Evidence map›Paper›PMID 26524953›Full record

ArticleScientific reports2015

Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.

Bo Pan, Jing Shen, Jingyan Cao, Yongxu Zhou, Lihua Shang, Shi Jin, Shoubo Cao, Dehai Che, Fang Liu, Yan Yu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 102 papers.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 161 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bo PanDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Jing ShenDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Jingyan CaoDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Yongxu ZhouDepartment of general surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, PR China.
Lihua ShangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Shi JinDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Shoubo CaoDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Dehai CheDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Fang LiuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Yan YuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, PR China.
Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CNFourth Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of IL-17-positive cells is observed in a variety of inflammatory associated cancers and IL-17 has been found to be involved in angiogenesis. However, it remains unclear how IL-17 might contribute to tumor angiogenesis. In our study, IL-17 enhanced the formation of vessel-like tubes in HUVECs both directly (when HUVECs were incubated with IL-17) and indirectly (when HUVECs were incubated in conditioned cell media (CCM) from IL-17-treated cancer cells). Our results from experiments using siRNA-mediated knockdowns of STAT3 and GIV suggest that the effects of IL-17 were mediated by activating STAT3/GIV signaling in NSCLC cells and subsequently up-regulating its downstream target VEGF. Consistent with these findings, immunostaining experiments on human NSCLC tissues indicated that IL-17 and GIV expression were significantly and positively associated with increased tumor vascularity. The clinical significance of IL-17 was authenticated by our finding that the combination of intratumoral IL-17 + cells and GIV expression served as a better prognosticator for survival than either marker alone. Therefore, our finding highlights a novel aspect of STAT3/GIV pathway in the IL-17 promotes tumor angiogenesis of NSCLC.

Indexed as

AgedCarcinoma, Non-Small-Cell LungCell Line, TumorCell SurvivalCulture Media, ConditionedCytokinesFemaleHumansHuman Umbilical Vein Endothelial CellsInterleukin-17Lung NeoplasmsMaleMicrofilament ProteinsMiddle AgedNeovascularization, PathologicNeovascularization, PhysiologicCCDC88A protein, humanCulture Media, ConditionedCytokinesInterleukin-17Microfilament ProteinsReceptors, Interleukin-17Recombinant ProteinsRNA, MessengerSTAT3 Transcription FactorVascular Endothelial Growth Factor AVesicular Transport Proteins

Identifiers

PMID26524953
PMCPMC4630609
OpenAlexW2185409974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.